Prognostic value of late gadolinium enhancement on cardiovascular magnetic resonance for noncompaction cardiomyopathy patients

Q: What does this research mean for the field?

Late gadolinium enhancement was present in 25% of noncompaction cardiomyopathy patients and predicted a 2.60-fold increased risk of adverse clinical events (HR=2.60). Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

Martijn Tukker; T G Gegenava; A H Hirsch; R A B De Boer; K N Nieman; K C Caliskan

doi:10.1093/eurheartj/ehaf784.282

November 1, 2025European Heart Journal

Prognostic value of late gadolinium enhancement on cardiovascular magnetic resonance for noncompaction cardiomyopathy patients

View Full Paper

Ask AI

Bookmark

Share

Key result

Late gadolinium enhancement was present in 25% of NCCM patients and predicted a 2.6-fold higher risk of a composite endpoint including death, HF hospitalization, and arrhythmia.

Why the study?

Current studies on the prevalence of late gadolinium enhancement in noncompaction cardiomyopathy are heterogeneous and inconclusive.

Does the presence of late gadolinium enhancement on CMR predict adverse clinical outcomes in adult patients with noncompaction cardiomyopathy?

Key Points

This study aims to evaluate the prevalence and prognostic significance of late gadolinium enhancement in patients with noncompaction cardiomyopathy.
Conducted a multicenter retrospective cohort study.
Included adult noncompaction cardiomyopathy patients with CMR images.
Assessed the impact of late gadolinium enhancement on clinical outcomes.
Established a composite primary endpoint of all-cause mortality and significant cardiac events.
25% of patients exhibited late gadolinium enhancement.
Patients with late gadolinium enhancement had a lower left ventricular ejection fraction (34% vs. 49%).
50% of patients with late gadolinium enhancement reached the composite endpoint compared to 15% without it.
Multivariate analysis indicated late gadolinium enhancement as a significant predictor of adverse outcomes.

Structured PICO

Does the presence of late gadolinium enhancement on CMR predict adverse clinical outcomes in adult patients with noncompaction cardiomyopathy?

P

Population

186 adult (≥16 years) patients with noncompaction cardiomyopathy (NCCM) with available cardiovascular magnetic resonance (CMR) images and late gadolinium enhancement (LGE) assessment. Mean age 41 ± 16 years, 52% male.

I

Intervention

Presence of late gadolinium enhancement (LGE) on cardiovascular magnetic resonance (CMR)

C

Comparator

Absence of late gadolinium enhancement (LGE) on cardiovascular magnetic resonance (CMR)

O

Outcome

Composite of all-cause mortality, heart failure hospitalization, cardiac resynchronization therapy (CRT), stroke, heart transplantation, left ventricular assist device, and ventricular arrhythmia (VA)composite

Implication

The presence of late gadolinium enhancement on CMR is found in 25% of adult NCCM patients and serves as a strong independent predictor of adverse cardiovascular events.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tukker et al. (2025) studied this question. Late gadolinium enhancement was present in 25% of NCCM patients and predicted a 2.6-fold higher risk of a composite endpoint including death, HF hospitalization, and arrhythmia.

synapsesocial.com/papers/698827670fc35cd7a88462cb https://doi.org/10.1093/eurheartj/ehaf784.282